| Assessment/Procedure |
Screening (Days) |
Treatment Period (Weeks) |
Follow-up (Weeks) |
| |
-35 to -1 |
BL |
1 |
2 |
4 |
8 |
12 |
18 |
24 |
32 |
40 |
48 |
52 |
60 |
72 |
| Informed Consent |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Complete Medical History, including family history of HBV |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HBV histological confirmation |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Physical examination |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ophthalmologic examination |
X |
Repeat in patients with preexisting findings or those developing symptoms |
| Vital Signs&Symptom-Directed Physical |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
| Urine or serum HCG Pregnancy |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chest x-ray (selected patients) |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ultrasound, CT or MRI (selected patients) |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Electrocardiogram (selected patients) |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alfa-fetoprotein |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-HAV IgM, anti-HCV, anti-HIV, anti-HDV |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| alfa 1, AT, AMA, ANA, ASMA |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hematology |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
|
| ALT only |
|
|
|
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
| Chemistry |
X |
X |
|
|
X |
|
X |
|
X |
X |
|
X |
X |
X |
X |
| HBeAg, anti-HBe |
X |
X |
|
|
|
|
opt |
|
opt |
opt |
|
X |
opt |
|
X |
| HBV DNA |
X |
X* |
|
|
|
|
opt |
|
opt |
opt |
|
X |
|
|
X |
| HBsAg, anti-HBs |
X |
|
|
|
|
|
|
|
|
|
|
X |
|
|
X |
| Adverse Events (h) |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
| Drug accountability/ compliance |
|
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
|
|
|
| Concomitant medication |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
X |
*opt - optional